Subsequently, several large clinical trials, including IPASS, WJTOG3405, NEJGSG002, OPTIMAL, EURTAC, and ENSURE, confirmed that gefitinib and erlotinib were superior to chemotherapy in NSCLC patients with EGFR mutations (especially sensitizing mutation, exon 19 deletion and exon 21 L858R) in terms of progression‐free survival (PFS), objective response rate (ORR), and quality of life, whereas these EGFR TKIs showed no advantage in patients without such mutation.55, 103, 104, 105, 106, 107. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.